Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
Total Valuation
Chemomab Therapeutics has a market cap or net worth of $12.30M. The enterprise value is $2.96M.
Market Cap$12.30M
Enterprise Value$2.96M
Share Statistics
Chemomab Therapeutics has 7,192,266 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,192,266
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Chemomab Therapeutics’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -78.18%.
Return on Equity (ROE)-0.74
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)-78.18%
Return on Capital Employed (ROCE)-0.78
Revenue Per Employee0.00
Profits Per Employee-453.32K
Employee Count20
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Chemomab Therapeutics is ―. Chemomab Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.85
Price to Fair Value0.85
Price to FCF-0.94
Price to Operating Cash Flow-1.17
PEG Ratio0.02
Income Statement
In the last 12 months, Chemomab Therapeutics had revenue of 0.00 and earned -9.07M in profits. Earnings per share was -1.42.
Revenue0.00
Gross Profit-70.56K
Operating Income-9.64M
Pretax Income-9.07M
Net Income-9.07M
EBITDA-9.57M
Earnings Per Share (EPS)-1.42
Cash Flow
In the last 12 months, operating cash flow was -11.22M and capital expenditures -3.03K, giving a free cash flow of -11.22M billion.
Operating Cash Flow-11.22M
Free Cash Flow-11.22M
Free Cash Flow per Share-1.56
Dividends & Yields
Chemomab Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-56.38%
50-Day Moving Average1.69
200-Day Moving Average2.75
Relative Strength Index (RSI)49.25
Average Volume (3m)207.96K
Important Dates
Chemomab Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Chemomab Therapeutics as a current ratio of 9.08, with Debt / Equity ratio of 0.00%
Current Ratio9.08
Quick Ratio9.08
Debt to Market Cap0.00
Net Debt to EBITDA0.79
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Chemomab Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Chemomab Therapeutics EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.26.
EV to Sales0.00
EV to EBITDA-0.31
EV to Free Cash Flow-0.26
EV to Operating Cash Flow-0.26
Balance Sheet
Chemomab Therapeutics has $10.37M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.37M billion.
Cash & Marketable Securities$10.37M
Total Debt$0.00
Net Cash$10.37M
Net Cash Per Share$1.44
Tangible Book Value Per Share$1.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Chemomab Therapeutics is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.00
Price Target Upside777.19% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast53.19%